Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targetable gene delivery vectors.

P L Hallenbeck, S C Stevenson

    Advances in Experimental Medicine and Biology
    |May 16, 2000
    PubMed
    Summary
    This summary is machine-generated.

    Developing targeted adenoviral vectors for cancer therapy requires identifying specific ligands that bind tumor cells. Advances in technology offer new opportunities for discovering these crucial ligands for future clinical applications.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Elevated expression of <i>ANTXR1</i> gene in tumors is a poor prognostic biomarker for patients with bladder cancer.

    Frontiers in molecular biosciences·2025
    Same author

    Synthesis of adenoviral targeting molecules by intein-mediated protein ligation.

    Gene therapy·2003
    Same author

    A genetically modified adenoviral vector exhibits enhanced gene transfer of human smooth muscle cells.

    Journal of vascular research·2001
    Same author

    Enhanced gene transfer to rabbit jugular veins by an adenovirus containing a cyclic RGD motif in the HI loop of the fiber knob.

    Journal of vascular research·2001
    Same author

    Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells.

    Journal of virology·2001
    Same author

    Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin.

    Human gene therapy·2000
    Same journal

    Peptidomics in the Spotlight: Advanced Sample Treatment Techniques and Analytical Insights.

    Advances in experimental medicine and biology·2026
    Same journal

    Methods for the Investigation of Protein-Ligands Interactions.

    Advances in experimental medicine and biology·2026
    Same journal

    Sample Preparation Strategies for Microbial Cell Surface Proteomics: Integrating Shaving and Shotgun Approaches.

    Advances in experimental medicine and biology·2026
    Same journal

    Proteomic Sample Preparation for the Petroleum Industry: A Biocorrosion Case Study.

    Advances in experimental medicine and biology·2026
    Same journal

    Proteomic and Functional Comparison of Extracellular Vesicles from Wild-Type and Lyn-Deficient Stromal Cells.

    Advances in experimental medicine and biology·2026
    Same journal

    Proteomic Analysis of Histone Sequence Variants and Post-translationally Modified Forms.

    Advances in experimental medicine and biology·2026
    See all related articles

    Area of Science:

    • Biotechnology
    • Gene Therapy
    • Oncology

    Background:

    • Adenoviral vectors are being engineered with targeting ligands for tumor cells.
    • These vectors lack natural tropism and carry therapeutic payloads.
    • Challenges remain in designing vectors with high affinity for tumor cells over normal cells.

    Purpose of the Study:

    • To explore the design and therapeutic use of targetable adenoviral vectors.
    • To identify novel ligands with higher affinity for tumor and/or tumor endothelial cells.
    • To assess the potential of emerging technologies in ligand discovery.

    Main Methods:

    • Utilizing advancements like human genome sequencing.
    • Employing in vivo and in vitro phage display techniques.

    Related Experiment Videos

  • Analyzing gene and protein expression for new cellular targets, including angiogenic endothelial cells.

    • Main Results:

    • Emerging technologies provide opportunities for discovering novel and useful ligands.
    • Growing interest in targeted vectors is evidenced by dedicated journals and meetings.
    • Significant progress is anticipated in the next five years.

    Conclusions:

    • Targetable adenoviral vectors hold promise for cancer therapy.
    • Continued research and technological advancements are key to overcoming design challenges.
    • Meaningful clinical data on targeted vectors is expected within five years.